Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy, in the majority of cases caused by mutations in the MLC1 gene. MRI from MLC patients shows diffuse cerebral white matter signal abnormality and swelling, with evidence of increased water content. Histopathology in a MLC patient shows vacuolation of myelin, which causes the cerebral white matter swelling. MLC1 protein is expressed in astrocytic processes that are part of blood-and cerebrospinal fluid-brain barriers. We aimed to create an astrocyte cell model of MLC disease. The characterization of rat astrocyte cultures revealed MLC1 localization in cell-cell contacts, which contain other proteins described typically in tight and adherent junctions. MLC1 localization in these contacts was demonstrated to depend on the actin cytoskeleton; it was not altered when disrupting the microtubule or the GFAP networks. In human tissues, MLC1 and the protein Zonula Occludens 1 (ZO-1), which is linked to the actin cytoskeleton, co-localized by EM immunostaining and were specifically co-immunoprecipitated. To create an MLC cell model, knockdown of MLC1 in primary astrocytes was performed. Reduction of MLC1 expression resulted in the appearance of intracellular vacuoles. This vacuolation was reversed by the co-expression of human MLC1. Reexamination of a human brain biopsy from an MLC patient revealed that vacuoles were also consistently present in astrocytic processes. Thus, vacuolation of astrocytes is also a hallmark of MLC disease.
INTRODUCTION
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) (OMIM 604004) is an unusual leukodystrophy (van der characterized by infantile onset macrocephaly, diffuse signal abnormality, swelling of the cerebral white matter and the presence of cysts in the anterior temporal regions (van der . Diagnosis is based on clinical and MRI criteria. A brain biopsy from an MLC patient showed that myelin was vacuolated (van der Knaap et al., 1996) .
The first disease chromosome locus was found in 2000 (Topcu et al., 2000) and the first disease gene in 2001 (Leegwater et al., 2001) . Mutations in the MLC1 gene are found in approximately 80% of the MLC patients (Ilja Boor et al., 2006; Leegwater et al., 2001; Leegwater et al., 2002; Montagna et al., 2006) ; there is evidence that other unknown genes are also involved (Blattner et al., 2003; Patrono et al., 2003) . MLC1 (the protein product of MLC1) is an oligomeric membrane protein with some degree of homology to ion channels (Leegwater et al., 2001; Teijido et al., 2004) . Mutations found in MLC patients reduce MLC1 protein expression (Duarri et al., 2008) . The physiological role of MLC1 is unknown. Based on the myelin vacuolation present in MLC patients and the low homology of MLC1 to ion channels, it has been suggested that MLC1 could have a role in ion transport processes linked to water movements. Unfortunately, functional evidence is lacking, because no ion channel activity has been detected after expression of MLC1 in heterologous systems (Kaganovich et al., 2004; Teijido et al., 2004) .
Within the brain, MLC1 is located in two populations: neurons and astrocytes (Boor et al., 2005; Schmitt et al., 2003; Teijido et al., 2004; Teijido et al., 2007) . In astrocytes, MLC1 is mainly present the processes that are in contact with blood-and cerebrospinal fluid-brain barriers (CSF). Electron microscopic immunohistochemistry indicated that, in mouse tissue, MLC1 is located in astrocyte-astrocyte contacts and not in astrocyte-endothelial contacts (Teijido et al., 2007) .
Here, we used rat primary astrocytes to understand the pathophysiological mechanisms of MLC. First, we characterized the endogenous MLC1 protein; and second, we reduced MLC1 expression and analyzed the consequences of this reduction. We then re-examined the human MLC brain tissue by EM to confirm the relevance of our findings.
MATERIALS AND METHODS

Animal experimentation and Human Samples
All the animal experimental protocols have been approved by the Animal Care and Ethics Committee of the University of Barcelona and conformed to the rules set by the Government of Catalunya. Human brain samples have been examined, registered, classified and stored following general consensus of the European Brain Bank Network at the Institute of Neuropathology Brain Bank at the Bellvitge Hospital. The anonymized register included age and gender, minimal clinical data set, postmortem delay and pH of the brain. Neuropathological diagnosis covered up to four neuropathological diagnoses of the primary disease and associated pathologies. Stage of the disease following internationally-accepted nomenclature is recorded in every case. MLC brain biopsy material was obtained for diagnostic purposes, as has been described previously (van der Knaap et al., 1996) .
Immunological procedures
Immune sera against N-terminal mouse MLC1 and the N4 anti-Nterminus of human MLC1 antibody were generated and characterized previously (Duarri et al., 2008; Teijido et al., 2004; Teijido et al., 2007) .
Primary culture and adenoviral transduction
Rat and mouse primary astrocyte cultures were prepared as described previously with some modifications (Duarri et al., 2008) . Briefly, cortex and hippocampus were removed from newborn Sprague Dawely rats or OF1 mice (Charles River). Rat astrocyte cultures were prepared from 1 to 3 days old rats while mouse astrocyte cultures were prepared from 0 to 1 day old OF1 mice. Cerebral cortices were dissected and the meninges were carefully removed in cold sterile 0.3% BSA, 0.6% glucose in PBS. The tissue was trypsinized for 10 min at 37°C and mechanically dissociated through a small bore fire-polished Pasteur pipette in complete DMEM medium (Dulbecco's Modified Eagle's Medium with 10% heatinactivated foetal bovine serum (Biological Industries), 1% penicillin/streptomycin (Invitrogen) and 1% glutamine (Invitrogen) plus 40 U/ml DNase I (Sigma)). The cell suspension was pelleted and re-suspended in fresh complete DMEM, filtered through a 100-µm nylon membrane (BD Falcon) and plated into 75 cm 2 cell culture flasks (TPP). When the mixed glial cells reached confluence, contaminating microglia, oligodendrocytes and precursor cells were dislodged by mechanical agitation and removed as previously described (McCarthy and de Vellis, 1980) . Astrocytes were plated in 6-wells plates, at density of 4·10 5 cells per well, or in poly-D-lysine-coated cover slips at 7,5·10 4 cells in 24-well plates. Medium was changed every 3 days. In order to obtain astrocyte cultures arrested in the cell cycle, medium was replaced and cytosine β-D-arabinofuranoside (AraC, Sigma) (2 µM) was added. Similarly, Fluo-uridine/uridine or dBAMPc were added at 20/50 µg/ml or 250 µM, respectively. Cultured astrocytes were identified by their positive GFAP (Glial Fibrillary acid protein) staining (Dako), being >95% of cells GFAP positive.
Treatment of cells with colchicine (10 µg/ml, Sigma) and Taxol (10 µM, Sigma) were performed during 20 hours (Sorci et al., 1998) , while incubation with cytochalasin-D (10 µM, Sigma) was performed during 2 hours (Nicchia et al., 2008) .
Construction of adenovirus expressing HA-tagged human MLC1 and transduction of astrocytes was previously described (Duarri et al., 2008) .
Immunofluorescence studies
Tissue immunohistochemistry was performed as previously described (Teijido et al., 2004; Teijido et al., 2007) .
For immunofluorescent staining of cells, these were fixed with PBS containing 3% paraformaldehyde for 15 min, blocked and permeabilized with 10% FBS and 0.1% Triton X-100 in PBS for 2h at room temperature (RT). Primary antibodies were diluted in the same solution and incubated over-night at 4°C. Antibodies used were already described Antimouse MLC1 and antihuman MLC1 (1:50), anti-ZO-1 (Zonula occludens 1) (1:100; Zymed), anti-NCadherin (1:100; Sigma), anti-β-Catenin (1:100; BD Transduction Lab.), anti-Occludin (1:100; Zymed), anti-Ezrin (1:200; Abcam), anti-Vinculin (1:1000; Zymed), anti-Connexin 43 (1:50; Zymed), Phalloidin-FITC (1:1000; Sigma), anti-β-Tubulin (1:1000; Chemicon), anti-GFAP (1:2000; Chemicon), anti-HA (haemagglutinin) 3F10 (1:500; Roche), anti-β-Dystroglycan (1:100; Novacastra), anti-α-Dystroglycan (1:30; Upstate), antiSyntrophin (1:80; Affinity Bioreagents), anti-β-Dystrobrevin (1:200; Ambrosini's lab). Cells were washed and incubated for 2 h at RT with secondary antibodies: Alexa-488 anti-mouse, Alexa-568 antirabbit, Alexa-568 anti-mouse and Alexa-488 anti-rabbit (1:500 dilution; Invitrogen). Coverslips were mounted in Vectashield medium (Vector Laboratories) with 1.5 µg/ml DAPI (Sigma) and visualized using an Olympus DSU spinning disk confocal microscope. Colocalization experiments were analyzed using ImageJ (http://rsbweb.nih.gov/ ij/).
Co-immunoprecipitation and Western blot
Rat brains were homogenized in immunoprecipitation buffer: 150 mM NaCl in PBS containing 1% Dodecyl-maltoside and protease inhibitors: 1 µM Pepstatin and Leupeptin, 1 mM Aprotinin and PMSF using a dounce homogenizer. Tissue lysates were incubated for 1 h at 4°C and centrifuged (5 min at 3000xg) to discard large debris, and proteins were quantified by the BCA kit (Pierce). 1-2 mg of antibodies against mouse MLC1, an irrelevant IgG or BSA were covalently linked to an agarose matrix as described in manufacturer's instructions (AminoLink Plus Immobilization Kit, Pierce). Antibody-linked agarose matrix was equilibrated in immunoprecipitation buffer and tissue lysate was added in a ratio of 10 µl (corresponding to about 10 µg of antibody):100 µg of protein and incubated 2 h at 4°C. Flowthrough was recovered by centrifugation and pellet was washed in the same buffer.
Immunoprecipitates were eluted in SDS loading sample buffer for 15 min at 60°C.
For Western blot studies, astrocyte lysates were prepared by homogenization of cells in PBS containing 1% Triton X-100 and protease inhibitors: 1 µM Pepstatin and Leupeptin, 1 mM Aprotinin and PMSF, incubated for 1 h at 4°C and centrifugated. Supernatants were quantified using BCA kit (Pierce) and mixed with SDS loading sample buffer. Western-blot analysis was performed as described (Teijido et al., 2004) . Membranes were incubated with primary antibodies: anti-MLC1 (1:100) and anti-β-Actin (1:10000, Sigma) and secondary antibodies: HRP-conjugated anti-rabbit and anti-mouse (1:10000; Jackson), respectively. Quantification of Western blots was performed by ImageJ.
Electron microscopy
Small human cerebellum samples were obtained post-mortem (Bellvitge Hospital), fixed in 4% PFA and 0.1% glutaraldehyde in 0.12 M phosphate buffer and processed. They were cryoprotected gradually in sucrose and cryofixed by immersion in liquid propane. Freeze substitution was performed at −90 °C during 3 days in an "Automatic Freeze Substitution System" (AFS, Leica), using methanol containing 0.5% uranyl acetate as substitution medium. Infiltration was carried out in Lowicryl HM20 at −50 °C and then polymerized with UV lamps. Ultrathin sections were collected and processed for a post-embedding immunostaining. Samples were incubated with rabbit anti-N4-human MLC1 (1:10) antiserum. For double immunostaining, grids were incubated with rabbit anti-N4-human MLC1 (1:10) and mouse anti-ZO-1 (1:10). The secondary antibodies were 18 nm goldconjugated goat anti-rabbit (British Biocell International; 1:20) and 12 nm colloidal goldcoated goat anti-mouse (British Biocell International; 1:20) . In control experiments, the primary antibodies were omitted -no immunogold labeling occurred under these conditions. MLC brain biopsy material was obtained from the right frontal region in a patient at the age of 13 years for diagnostic purposes (van der Knaap et al., 1996) . Ultra-thin sections were collected on Formvar-coated copper grids, stained with lead citrate and uranyl-acetate, and examined by electron microscope (JEOL1010).
RNA interference
RNAi entry-clones (Gateway, Invitrogen) vectors were prepared using the Block-it PolII miR RNAi EmGFP expression vector kit following manufacturer's instructions. The sequence of the oligos used was: shRNA Scrambled (negative control): 5'aaatgtactgcgcgtggagacgttttggccactgactgacgtctccacgcagtacattt3'; shRNA756 (against rat MLC1): 5'tgcacagcgcaaataatccatgttttggccactgactgacatggattatgcgctgtgca3'; shRNA905 (against rat MLC1): 5'ttcaggatcaatttgcatccagttttggccactgactgactggatgcattgatcctgaa. Entry clones were recombined using LR clonase into the vector pAdVDEST-CMV/V5. Adenoviruses were produced and titrated using flow cytometry detecting the EmGFP which is expressed together with the shRNA.
Real-time PCR
Total RNA was prepared from one 10 cm-culture plate using NucleoSpin RNA/Prot (Macherey-Nagel) as indicated by the manufacturer. RNA concentration was determined in a Nanodrop spectrophotometer. All samples had an A260/A280 ratio > 1.8. RIN value was obtained with the RNA 600-nano (Agilent) following manufacturer instructions and calculated with 2100 Expert Software B.02.07 (Patch 01). All RNA samples were above 8. RNA was stored at −80°C until further use.
800-1000 ng of total RNA were reverse-transcribed with Transcriptor First Strand cDNA synthesis kit (Roche) following manufacturer instructions at 25°C for 10 min followed by 50°C for 60 min, using random hexamers as primers. cDNA was stored at −80°C. qPCR was performed with Lightcycler 480 probes master kit (Roche) following manufacturer instructions in a final volume of 10 µl, with cDNA at 1:50 dilution. The primers and UPLprobes used were designed with the ProbeFinder version 2.45 (Roche) by the on-line application (https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000) considering exon spanning and trying to cover all splice variants. qPCR was run in a LightCycler 480 II on 384-well plates. Gene expression was normalized against ACTB (β-Actin) and efficiency curves were used for each of the analyzed genes. All amplifications were within the linear range. Data came from 4 different astrocyte preparations. Means of triplicates were used for each analysis. The standard deviation of the triplicates was 0.2 or lower. Data analysis was performed using LightCycler 480SW 1.5 software (Roche), MSAccess 2010 and MS-Excel 2010. Outliers and extremes were identified with SPSS v.12 and removed from the analysis. Significance was calculated using a Bootstrap method (Cleries et al, submitted). All primers used are presented in Supplementary Table 1 .
RESULTS
Expression of MLC1 in primary astrocyte cultures
Previous studies on brain tissue identified MLC1 in astrocyte-astrocyte plasma membrane contact regions in Bergmann glia and astrocytic processes surrounding blood vessels (Teijido et al., 2007) . We aimed to study the role of MLC1 in astrocyte physiology to understand the molecular pathogenesis of MLC. In primary rat astrocytes, endogenous MLC1 was detected mostly in a diffuse intracellular localization through the cytoplasm. Since expression of other transporters or channels in astrocytes depends on the metabolic state of the cell (Ferroni et al., 1997) , we analyzed MLC1 expression and localization in astrocyte cultures treated with compounds that block cell proliferation and/or cause cell differentiation (see Methods).
Increased protein expression was detected in arrested astrocyte long-term cultures ( Figure  1A ). In these cells, MLC1 localization began to appear at the plasma membrane after 1 week ( Figure 1B) , and it was clearly detected in astrocyte processes and junctions after 3 weeks in culture ( Figure 1C ).
In order to clarify in which type of junctions MLC1 is located, we performed double immunofluorescence studies using different protein markers related to cell junctions or adhesion. A high degree of co-localization was observed between MLC1 and components of tight junctions such as Zonula Occludens 1 (ZO-1) (Fanning and Anderson, 2009 ) ( Figure  1D ) and Occludin (Hirase et al., 1997) (Figure 1E ). Similarly, there was a high degree of colocalization with components of adherent junctions, such as β-Catenin (Perego et al., 2002) (Figure 1F ). Connexin 43 (Cx43), a typical component of astrocytic gap junctions (Rouach et al., 2000) co-localized with MLC1 partially ( Figure 1G) ; while MLC1 was distributed along the membrane protrusion joining two cells, Cx43 was localized in discrete spots through the membrane protrusion. Vinculin, a typical marker of focal adhesions (Kalman and Szabo, 2001 ) ( Figure 1H ) and Ezrin, a protein located in developing astrocyte processes (Derouiche and Frotscher, 2001) , did not co-localize with MLC1 ( Figure 1I ). Similar co-localization patterns were found in mouse astrocytes (data not shown).
Relationship between MLC1 localization and the cytoskeleton
Next, we asked whether cytoskeleton could play a role in the localization of MLC1. For this, we used double immunostaining of MLC1 and markers of cytoskeletal elements combined with chemical and genetic inhibitors to perturb specific types of network filaments.
As shown in Figure 2A , phalloidin-stained actin filaments were present in MLC1 positive astrocyte junctions. Partial disruption of the actin network with low concentrations of cytochalasin-D (cyt-D) caused cell shrinkage without causing disturbances in MLC1 localization ( Figure 2B ). High concentrations of Cyt-D completely abolished MLC1 localization in these junctions ( Figure 2C ).
In contrast, microtubules (stained with β-tubulin) were not present in MLC1-positive junctions ( Figure 2D ), nor was MLC1 localization changed after microtubule disruption caused by a treatment with colchicine ( Figure 2E ), or microtubule stabilization using the inhibitor taxol ( Figure 2F ).
Regarding intermediate filaments, some colocalization of MLC1 and GFAP was detected within these astrocyte junctions ( Figure 2G ). Transfection of cells with constructs of GFAP fused to GFP (green fluorescence protein) containing a dominant mutation (p.Arg239Cys) found in Alexander disease is known to disorganize astrocyte intermediate filaments formed by GFAP (Mignot et al., 2007) . In astrocytes transfected with the wild-type GFAP or the GFAP R239C dominant mutant, MLC1 localization was unchanged in astrocyte junctions. Moreover, MLC1 localization was not altered in a mouse model of Alexander disease (Hagemann et al., 2006) Figure 1A and 1B) or in a human brain from a patient with Alexander disease (de novo c.1246C>T / p.Arg416Trp mutation in GFAP) (Supplementary Figure 1C) .
(Supplementary
Interaction of MLC1 with ZO-1
These results suggest that MLC1 localization is mainly dependent on an intact actin filament network. We reasoned that localization of MLC1 in these astrocytic junctions could also depend on interactions with the actin-binding ZO-1 protein. Therefore, coimmunoprecipitation experiments were performed ( Figure 3A) . Immunoprecipitation using MLC1 antibody-coupled beads was highly efficient and specific, as almost no MLC1 was detected in the non-bound fraction and no MLC1 was detected in the immunoprecipitate with an unrelated IgG ( Figure 3A ). In the MLC1 immunoprecipitate, a specific protein band around 220 kDa detected by a ZO-1 antibody was also copurified ( Figure 3A) . Similar results were found using other MLC1 antibodies (data not shown).
In contrast, analogous co-immunoprecipitation experiments to detect other proteins located at astrocyte junctions (occludin, β-catenin, N-cadherin and vinculin) or those forming part of the Dystrophin Glycoprotein Complex (DGC) (Haenggi and Fritschy, 2006) , which has been shown to be related with MLC1 (Ambrosini et al., 2008; Boor et al., 2007; Lanciotti et al., 2009) , resulted in no co-immunoprecipitation (Supplementary Figure 2A) . Furthermore, we studied whether the ClC-2 chloride channel could be co-immunoprecipitated with MLC1, because its KO mouse displayed a myelin vacuolation similar to what has been detected in MLC patients (Blanz et al., 2007) , but no coimmunoprecipitation was detected ( Supplementary Figure 2A) .
To extend these results from rat astrocyte cultures to human tissues, double EM immunostainings were performed in human brain tissue. We used high-resolution EM to clearly distinguish between astrocyte-endothelial and astrocyte-astrocyte contacts around blood vessels. First, antibodies against MLC1 and β-Dystroglycan were used ( Figure 3B ). The DGC protein β-Dystroglycan was used as a marker of astrocyte-endothelial junctions. As already described (Haenggi and Fritschy, 2006) , small gold particles corresponding to β-Dystroglycan were detected in astrocyte membranes contacting basal laminae. In contrast, larger gold particles, corresponding to MLC1 protein, were located only at the dense junctions of point contact (puncta adhaerens) seen between astrocytes. In agreement with MLC1 not being colocalized with the DGC at points of interaction between astrocytes and endothelial cells, no change in MLC1 localization was found in several DGC-null brains including Dystrophin KO (mdx β-geo ), α -Dystrobrevin KO and Utrophin KO mice (Supplementary Figures 2B-E ).
Similar to rat astrocyte cultures, ZO-1 ( Figures 3C and 3D ) colocalizes with MLC1 in astrocyte-astrocyte junctions in the human tissue. Although ZO-1 is typically expressed in endothelial cells, many groups have detected additional expression in astrocytes (Li et al., 2004; Penes et al., 2005) . The specificity of the antibody used against ZO-1 was evident, since it also detected ZO-1 in endothelial cell junctions (see inset of Figure 3C for ZO-1) (Fanning and Anderson, 2009 ).
Experimental approach to create an astrocyte cell model with reduced MLC1 expression
As the subcellular localization of MLC1 in quiescent primary rat astrocyte culture was found comparable to what was detected in brain tissue, it was concluded that such astrocytes could be used as a cellular model to address the functions of MLC1. Recent work showed that mutations found in MLC patients cause complete lack of MLC1 protein (Duarri et al., 2008) . Therefore, our next aim was to study the consequences of a reduction in the expression of MLC1 in this cell model. We produced two adenoviral vectors each expressing a distinct shRNA (756, 905) against rat MLC1 together with the fluorescent protein EmGFP, allowing visualization of transduced cells. A vector expressing shRNA without homology to any mammalian cDNA (SCR) was used as a control. To validate that the levels of MLC1 mRNA were reduced, we performed RT-PCR experiments 3 days after the infection with the adenovirus (performed at the multiplicity of infection (MOI) of two viruses per cell) ( Figure 4A ). MLC1 mRNA levels were nearly depleted in astrocytes infected with vectors expressing shRNA directed against MLC1, but were unaffected by the control shRNA (SCR).
Time course Western blot experiments performed after transduction at the same MOI showed that 5 days after the infection, almost no MLC1 protein was detected in astrocytes infected with the MLC1 shRNA ( Figure 4B ). Similar results were obtained by immunofluorescence ( Figure 4C ), additionally confirming that the signal detected in astrocyte junctions in previous experiments was related to MLC1 and not to other proteins detected by our antibodies.
As an additional control, astrocytes were depleted of endogenous MLC1 by the action of shRNA, and afterwards, they were complemented with the adenovector expressing HAtagged human MLC1 (HAhMLC1), which was resistant to this shRNA ( Figure 4C ).
Next, we aimed to further deplete or totally eliminate MLC1 expression in the primary cultures. Cells infected at MOIs higher than 20 began to show signs of mortality irrespective of the adenovector, including the control type (not shown). Following further titration experiments we selected a MOI of 5 as the highest dose of vector not showing any toxic effects.
Reduction of MLC1 expression caused vacuolation of astrocytes in primary cultures and in human MLC brain
Cells depleted of MLC1 displayed intracellular vacuoles scattered through the cytosol. This effect was observed for every of the shRNAs against MLC1 ( Figure 5B and Figure 5C or 5D for shRNA 756 and 905, respectively), but rarely occurred in non-transduced astrocytes, or astrocytes expressing the control shRNA ( Figure 5A ). We quantified the number of cells showing vacuolation (defined as number of cells with at least three vacuoles of a size bigger than 0.5 µm) in seven to eight independent experiments (8 exp, N = 758 cells for shRNA SCR; 7 exp, N = 591 cells for shRNA 756; 8 exp, N = 1063 cells for shRNA 905). Vacuolation occurred in 31.9 ± 5.4 % of the infected cells with shRNA 756, 32.6 ± 5.3 % in cells with shRNA 905 and 6.8 ± 1.8 % in the cells expressing the shRNA SCR.
To ensure that the defects observed in shRNAs directed against MLC1 transduced astrocytes were due to the lack of MLC1 and not to side effects of the shRNAs expression, coexpression experiments with human MLC1 (hMLC1) were performed (4 to 5 independent experiments; N = 654 cells for shRNA SCR + hMLC1, N = 604 cells for shRNA 756 + hMLC1, N = 762 cells for shRNA 905 + hMLC1). As shown in Figure 5E , cells depleted of endogenous MLC1 and complemented with human MLC1 displayed a significantly lower percentage of vacuolation (7.9 ± 1.5 % versus 31.9 ± 5.4 % for shRNA 756 ± hMLC1; 6.8 ± 1.7 % versus 32.6 ± 5.3 % for shRNA 905 ± hMLC1).
Because of these results, we re-examined by electron microscopy examination the brain biopsy of an MLC patient (van der Knaap et al., 1996) . These studies revealed again countless fluid-filled vacuoles in myelin sheaths ( Fig. 6A and B) , as described previously (van der Knaap et al., 1996) . Additionally, vacuoles were consistently found within all perivascular astrocytic endfeet within the sections examined (Fig. 6C ). Mitochondria were well preserved, indicating that the vacuole formation was not due to inadequate fixation.
The correlation between the vacuolation observed in MLC1-depleted astrocytes and the astrocytic vacuoles in MLC brain tissue suggested that this cellular model could be useful to study the pathogenesis of MLC.
Loss of MLC1 results in mRNA expression changes of transporters involved in cell volume regulation
Our first objective was to detect whether loss of MLC1 affected the levels of specific proteins associated with cell-cell junctions. Moreover, we analyzed levels of ClC-2 protein, which has also been detected in astrocyte-astrocyte junctions (Sik et al., 2000) . At least three independent experiments for ZO-1, β-Catenin, Occludin, Paxillin or ClC-2 revealed no changes in expression of the respective proteins after MLC1 depletion ( Figure 7A) . Similarly, no changes in protein localization were found for β-Catenin, Cx43, ZO-1 and Occludin (Supplementary Figure 3) . Unfortunately, the available antibodies against ClC-2 detected a diffuse signal in control astrocytes only, thus were not suitable for determining the localization of ClC-2 in these cells.
The homology of MLC1 to ion channels is suggestive of a function related with ion homeostasis, which would influence cell volume. Vacuolation of astrocytes with reduced MLC1 expression could also be indicative of a defect in water and/or cell volume regulation. Therefore, we measured the mRNA levels for several genes involved in cell-volume regulation in astrocytes after depletion of MLC1 ( Figure 7B ). These genes included the potassium-chloride cotransporter KCC1 (Ernest et al., 2005) , the sodium-bicarbonate cotransporter NBC (Nagelhus et al., 2004) and the sodium-potassium chloride cotransporter NKCC1 (Su et al., 2002) , and performed real-time PCR experiments after MLC1 depletion. In four independent experiments we observed a substantial increase in expression for KCC1 (5.32 ± 1.57 fold for shRNA 756; 6.8 ± 1.1 fold for shRNA 905), a moderate increase for NKCC1 (1.63 ± 0.15 fold for shRNA 756; 1.42 ± 0.07 fold for shRNA 905) and a moderate decrease for NBC (0.55 ± 0.40 fold for shRNA 756; 0.39 ± 0.15 fold for shRNA 905). Notably, transduction with SCR shRNA also induced KCC1 expression when compared with control astrocytes (1.96 ± 0.6), but the level of induction was much higher in astrocytes infected with shRNA against MLC1. However, when analyzing at the same time point after adenoviral transduction, the levels of KCC1 protein expression by Western blot no statistical differences were observed ( Figure 7A ).
DISCUSSION
The present study extends our knowledge on the important factors for MLC1 localization in astrocytes and provides a cell model to study the pathophysiology of MLC disease.
Results obtained from rat and mouse astrocytes and from mouse and human tissue localize MLC1 in astrocyte-astrocyte contacts. Colocalization experiments between MLC1 and other junctions proteins indicate that these contain components typically described in tight (Occludin, ZO-1), adherent (β-Catenin) and gap junctions (Cx43). Co-immunoprecipitation and colocalization experiments suggest that anchoring of MLC1 at these junctions involves an interaction with the adaptor molecule ZO-1. The protein ZO-1 is a member of the membrane-associated guanylate kinase (MAGUK) homologue family of proteins (Fanning and Anderson, 2009) , which work as a regulated scaffold for tight junction proteins due to its ability to bind to the cortical actin cytoskeleton.
Tight junctions in astrocytes have also been described by other authors (Mack and Wolburg, 2006; Wolburg et al., 1983; Wolburg et al., 2009) . A previous study (Duffy et al., 2000) reported that after treatment with Interleukin-1-beta (IL-1β), human foetal astrocytes expressed the typical tight junction molecule Claudin 1 and formed another type of junction that the authors called tight junction-like structures. An open question is whether these junctions are able to form a barrier to the flux of molecules, as several studies indicate that astrocytes do not contribute per se to blood-brain barrier properties in mammals (Wachtel et al., 2001 ). However, as astrocytic perivascular endfeet cover the vessel wall completely (Mathiisen et al., 2010) , astrocytes must be involved in the exchange of water and solutes between blood and brain, although the understanding of the mechanisms employed is incomplete.
Our results indicate that MLC1 is linked to the actin cytoskeleton, as its localization was altered with cyt-D, but not when disrupting the microtubule network. MLC and Alexander disease are both leukodystrophies in which astrocytes are affected and which share some phenotypic features (Gorospe and Maletkovic, 2006) . We investigated whether MLC1 localization is altered after transfection of a dominant mutant of GFAP or in Alexander disease models. This work indicates that MLC1 localization is not dramatically altered in these models, suggesting that the localization of MLC1 is not related with the integrity of the intermediate filament network. In line with this data, Vinculin, which does not colocalize with MLC1, was altered in astrocytes from GFAP mutant mice (Cho and Messing, 2009) , suggesting that the integrity of the GFAP network is important for correctly located focal adhesions, but not for the stability of junctions between astrocytes.
There are differences between these and previous results from us and other groups in the localization of MLC1 (Ambrosini et al., 2008; Boor et al., 2007; Lanciotti et al., 2009) . Some data suggesting that MLC1 formed part of the DGC were based on colocalization analyses using confocal microscopy (Ambrosini et al., 2008; Boor et al., 2007; Boor et al., 2005; Teijido et al., 2004) . In view of the small distances between different membranes at and between the endfeet, a high resolution technique such as electron immunogold immunocytochemistry is advisable (Teijido et al., 2007) . Taking the new data into account, we favour the idea that MLC1 is not located in areas of astrocytic processes contacting endothelial cells, but rather in areas of astrocytic processes that link astrocytes with each other. Interestingly, the DGC itself is also involved in the organization and maintenance of junctional complexes during development (Nico et al., 2003; Nico et al., 2004; Sjo et al., 2005) . Considering the data from other authors (Ambrosini et al., 2008; Boor et al., 2007) , the exact relationship between the DGC and the localization of MLC1 still needs to be clarified. An interesting unifying hypothesis that could explain these differences is that MLC1 expressed in different compartments might associate with different protein complexes having distinct physiological roles.
Although MLC1 was coimmunoprecipitated with the ZO-1 protein, a protein detected in astrocyte cell junctions, reduction of MLC1 protein levels did not cause any alteration in protein levels or in its subcellular localization in this protein or in the other junctional proteins studied. We interpret this data as MLC1 not being necessary for the formation and maintenance of these junctions.
In agreement with the suggested role of MLC1 in ion/water homeostasis, reduction of MLC1 protein levels cause vacuolation in astrocytes. In the initial characterization of the brain biopsy of an MLC patient (van der Knaap et al., 1996) , the number of large intramyelinic vacuoles was overwhelming. At reexamination of the EM tissue, we specifically focused on astrocytic processes, where MLC1 is located. This study revealed that all astrocytic processes in the sections examined consistently contain vacuoles. We conclude then that astrocytic endfeet vacuolation is also a hallmark of MLC disease. Whether the vacuoles detected in myelin are due to non-cell autonomous effects or due to the lack of MLC1 in neurons still need to be clarified.
Similar to the vacuolation detected in MLC patients, the knockout mouse of the ClC-2 chloride channel displayed myelin vacuolation (Blanz et al., 2007) . Because the knockout mice also displayed alterations in other tissues than brain, such as blindness and infertility (Bosl et al., 2001) , we reasoned that CLCN2 was unlikely to be another MLC disease gene. In agreement with this reasoning, no mutations were found in MLC patients without mutations in the MLC1 gene and without linkage to the MLC1 locus (Scheper et al., 2010) . Our data cannot exclude that the ClC-2 protein may be involved in the pathogenesis of the disease, but indicate that there is not a direct association between MLC1 and the ClC-2 proteins.
The initial set of experiments, aimed to understand the vacuolation that occurs after MLC1 depletion, showed that these astrocytes had increased levels of mRNA for KCC1 and NKCC1. In contrast and by unknown mechanisms, the protein level of KCC1 was unchanged. These proteins have been described to play a role in Regulatory Volume Decrease (RVD) and Regulatory Volume Increase (RVI) processes in glioma cells, respectively (Ernest et al., 2005; Pasantes-Morales et al., 2006; Su et al., 2002) . We speculate that the changes in the expression are a consequence of the vacuolation and do not drive this process, as vacuolation was not observed in KO mice and in patients with mutation in these genes (Delpire et al., 1999; Igarashi et al., 1999; Rust et al., 2007) . The precise mechanism of how the lack of MLC1 causes the vacuolation of astrocytes still needs to be clarified.
In conclusion, this work provides the first cellular model of MLC disease, that mimics the phenotypic features found in an MLC patient. The astrocyte culture described here constitutes a good starting cell model to study the molecular basis of the processes that are involved in the pathogenesis of MLC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. (A) Rat brain membranes were solubilized (Sol), and then immunoprecipitated using anti-MLC1 coupled beads. No MLC1 was detected in the not-bound (Nb) fraction or in the immunoprecipitate with an unrelated IgG (IP IgG). MLC1 immunoprecipitate showed a specific ~225 kDa protein band detected by the antibody directed against ZO-1. (B) EM double immunostaining with anti-human MLC1 and β-Dystroglycan antibodies showed that the latter is expressed in astrocyte membranes in contact with the basal lamina, whereas MLC1 is located at the cell contacts between astrocytes. Scale bar: 500 nm (C, D) Examples of double immunolabelling showing co-localization of MLC1 (18 nm gold particles) and ZO-1 (12 nm gold particles, arrows) in astrocyte-astrocyte junctions in human tissue. Antihuman MLC1 antibody showed post-embedding staining in astrocyte-astrocyte junctions and co-localized with ZO-1 (arrows in D) in human cerebellum. Note that ZO-1, but not human MLC1, is also expressed in junctions between endothelial cells (C, boxed area at higher magnification at the top right, arrows). D shows a higher magnification image observed in C. Arrows point to sites of ZO-1 expression. Scale bars in C, D: 500 nm; boxed (A) RT-qPCR experiment using specific primers to detect MLC1 mRNA. Data represent the mean ± SEM of 4 different astrocyte preparations either control or treated with indicated shRNAs. Both shRNA 756 and 905 caused almost complete inhibition of mRNA expression. ****, P < 0.0005 (B) Astrocytes (untreated or transduced at MOI 2 with shRNA SCR, shRNA 756 and shRNA 905) were analyzed after 2, 5, 8 or 12 days by Western blot using antibodies against MLC1, which was detected mainly as a monomer and as a dimer. β-Actin was used as a loading control. Note that increasing the time after the transduction resulted in further reduction of MLC1 expression. Representative results of up to 10 different experiments are shown. (C) Control or astrocytes transduced at MOI 2, 7 days after the treatment, were fixed and processed for immunofluorescence using antibodies against MLC1. Transduced cells were visualized by the positive GFP signal. Note that MLC1 signal is detected in control cells and cells infected with the SCR shRNA but not in cells infected with the shRNA 905. Right-hand panel: cells were co-transduced with shRNA 905 at MOI 2 and HA-tagged human MLC1 (resistant to shRNA) at MOI 1. Immunofluorescence, obtained using antibodies against the HA epitope. Scale bar: 20 µm The data correspond to 4 to 8 independent experiments with the number of cells analyzed for each shRNA as follows: shRNA SCR (n=758), shRNA 756 (n=591), shRNA 905 (n=1063), shRNA SCR + hMLC1 (n=654), shRNA 756 + hMLC1 (n=604), and shRNA 905 + hMLC1 (n=762). The degree of vacuolation was quantified manually using images prepared in Adobe Photoshop. Significance was compared in the groups 756 and 905 vs SCR (black stars), and between the groups 756 and 905 versus 756 + MLC1 and 905 + MLC1, respectively (grey stars). **, P < 0.01; ***, P < 0.005 (A) 7 days after shRNA adenovector-mediated expression, cell extracts were analyzed in Western blots using antibodies against specific proteins. The result shown is representative of at least three independent experiments. Quantification using ImageJ of these different experiments revealed that levels of the different proteins studied were not statistically different in cells treated with the shRNA against MLC1 vs. controls or cells transduced with SCR shRNA (data not shown). (B) RT-qPCR experiments using specific primers to detect KCC1, NBC and NKCC1 mRNAs. Data represent the mean ± SEM of 4 different astrocyte preparations treated as indicated. **, P < 0.01; ****, P < 0.0005.
